Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2022, specifically reporting transaction notifications dated June 23, 2022. The document details share allocation arrangements for Non-Executive Directors for the service period of April 1, 2022, to June 30, 2022.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions involving the acquisition of notional shares by Persons Discharging Managerial Responsibilities (PDMRs).
| Instrument | Price | Total Volume (Shares/ADSs) |
|---|---|---|
| Ordinary Shares (GBP) | £16.91 | 4,342.844 |
| American Depositary Shares (USD) | $41.62 | 3,658.782 |
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported changes are the specific share acquisitions by individual directors as part of standard compensation arrangements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of director share transactions.
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs acquired by Non-Executive Directors during the Q2 2022 service period.
- Confirm the transaction price of £16.91 per Ordinary Share and $41.62 per ADS reflects the market value on June 23, 2022.
- Note that this filing does not reflect executive management (CEO/CFO) transactions, only Non-Executive Directors.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this Form 6-K is limited to transaction notifications.